Drug Profile
Research programme: vanilloid 1 receptor antagonists - Amorepacific/Schwarz Pharma
Alternative Names: PAC 20030; SPM 95; SPM 955; Vanilloid 1 receptor antagonists - Schwarz/AmorepacificLatest Information Update: 26 Jun 2012
Price :
$50
*
At a glance
- Originator Amorepacific
- Developer UCB
- Class Analgesics
- Mechanism of Action TRPV cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 26 Jun 2012 Discontinued - Preclinical for Pain in Germany (unspecified route) before 2012
- 17 Jul 2007 Preclinical development is ongoing
- 04 Jan 2007 Schwarz Pharma has been acquired by UCB